FDA Response Confirms Senators On Right Trail About N.Y. Herbal Product Tests
This article was originally published in The Tan Sheet
Executive Summary
“FDA does not use DNA sequencing by itself to analyze an herbal extract for phytochemicals,” Associate Commissioner for Legislation Thomas Kraus tells Senators Hatch and Heinrich. The senators gave FDA an opportunity, without asking for a comment on an ongoing New York investigation, to describe the agency’s regulation of supplement manufacturing.
You may also be interested in...
New York AG Plies Third Pact Pushing DNA Testing On Supplement Firms
NBTY notes that FDA regulations allow firms flexibility in test methodologies for ingredient identity and other testing required under the supplement GMP final rule, and industry stakeholders say compliance with the GMPs is the standard, not a state agency's preferences.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.